PWAM
EGRX

Park West Asset Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Park West Asset Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-449,479
Closed -$18.8M – 193
2021
Q1 		$18.8M Sell
449,479
-342,121
-43% -$15.9M 0.57% 51
2020
Q4 		$36.9M Buy
791,600
+155,062
+24% +$7.25M 0.76% 30
2020
Q3 		$27M Sell
636,538
-483,697
-43% -$21.2M 1.05% 37
2020
Q2 		$53.7M Sell
1,120,235
-114,621
-9% -$5.72M 2.66% 12
2020
Q1 		$56.8M Buy
1,234,856
+62,976
+5% +$3.16M 3.86% 6
2019
Q4 		$70.4M Buy
1,171,880
+78,581
+7% +$4.69M 2.96% 10
2019
Q3 		$61.8M Sell
1,093,299
-206,701
-16% -$11.6M 3.01% 8
2019
Q2 		$72.4M Buy
1,300,000
+254,689
+24% +$13.3M 3.01% 8
2019
Q1 		$52.8M Sell
1,045,311
-4,689
-0.4% -$209K 2.32% 13
2018
Q4 		$42.3M Buy
1,050,000
+308,574
+42% +$15.9M 2.09% 13
2018
Q3 		$51.4M Sell
741,426
-362,130
-33% -$27.5M 1.87% 17
2018
Q2 		$83.5M Buy
1,103,556
+52,282
+5% +$3.29M 3.11% 8
2018
Q1 		$55.4M Buy
1,051,274
+15,000
+1% +$872K 2.47% 12
2017
Q4 		$55.4M Buy
1,036,274
+128,054
+14% +$7.13M 2.52% 13
2017
Q3 		$54.2M Buy
908,220
+501,557
+123% +$30.3M 3.23% 9
2017
Q2 		$32.1M Sell
406,663
-81,465
-17% -$6.66M 1.78% 22
2017
Q1 		$40.5M Sell
488,128
-91,625
-16% -$6.81M 2.36% 13
2016
Q4 		$46M Sell
579,753
-50,000
-8% -$3.63M 3.56% 10
2016
Q3 		$44.1M Hold
629,753
– – 4.01% 9
2016
Q2 		$24.4M Sell
629,753
-842,444
-57% -$35.1M 2.47% 14
2016
Q1 		$59.6M Buy
1,472,197
+782,197
+113% +$49.6M 5.61% 2
2015
Q4 		$61.2M Buy
690,000
+189,409
+38% +$15M 6.6% 1
2015
Q3 		$37.1M Sell
500,591
-2,994
-0.6% -$249K 3.38% 8
2015
Q2 		$40.7M Sell
503,585
-121,335
-19% -$7.9M 3.78% 8
2015
Q1 		$26.2M Sell
624,920
-175,080
-22% -$4.97M 3.82% 8
2014
Q4 		$12.4M Buy
800,000
+132,538
+20% +$1.69M 1.97% 20
2014
Q3 		$8.44M Buy
667,462
+240,562
+56% +$2.98M 1.25% 26
2014
Q2 		$6.12M Buy
426,900
+217,700
+104% +$2.48M 0.8% 34
2014
Q1 		$2.67M Buy
+209,200
New +$2.84M 0.3% 54

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SGCIA
Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Park West Asset Management's EGRX Position: Q2 2021 in Review

Park West Asset Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2021, closing a stake of 449,479 shares — an estimated $18.8M sold.

Park West Asset Management first reported a position in EGRX in Q1 2014 and held it in 29 quarters. The position peaked at $83.5M in Q2 2018. 146 funds tracked by Wall St. Rank hold EGRX as of Q2 2021.

  • Park West Asset Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
  • Park West Asset Management sold 449,479 Eagle Pharmaceuticals, Inc. shares in Q2 2021, an estimated $18.8M.
  • Park West Asset Management first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2014 and held it in 29 quarters.
  • Park West Asset Management's Eagle Pharmaceuticals, Inc. position peaked at $83.5M in Q2 2018.
  • 146 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2021.

Based on Park West Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.